` LYTIX (Lytix Biopharma AS) vs Oslo OBX Comparison - Alpha Spread

LYTIX
vs
Oslo OBX

Over the past 12 months, LYTIX has underperformed Oslo OBX, delivering a return of -9% compared to the Oslo OBX's 16% growth.

Stocks Performance
LYTIX vs Oslo OBX

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
LYTIX vs Oslo OBX

Loading
LYTIX
Oslo OBX
Difference

Performance By Year
LYTIX vs Oslo OBX

Loading
LYTIX
Oslo OBX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Lytix Biopharma AS vs Peers

Oslo OBX
LYTIX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Lytix Biopharma AS
Glance View

Market Cap
300.5m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.86 NOK
Overvaluation 85%
Intrinsic Value
Price
L
Back to Top